Versantis is focused on liver disease and develops VS-01 for hepatic encephalopathy in patients with decompensated cirrhosis. Its lead candidate, VS-01, is entering the Ph.1b clinical stage in 2019. It was granted Orphan Drug Designations (FDA/EMA) which will expedite its overall clinical program.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2015
  • Number of employees in Switzerland
    1-9
Key business